My passion lies in driving innovation via robust platforms and methods and fostering collaborative environments to create impactful solutions for clients, patients, and communities.

As a scientist, I tackled challenges in RNA biology, sequencing technology, and genetic medicines, and applied the solutions toward diagnostics and treatments for infectious, immunological, and rare diseases. Early in my career, I made key discoveries in the RNA interference pathway, specifically how small RNAs are assembled into effector complexes and are stabilized through RNA modification. As a research scientist at the Broad Institute, I developed methods for next-generation sequencing (NGS) of viral genomes from clinical samples to generate ‘open access’ data from outbreaks of deadly RNA viruses like Ebola. As it was a consortium research endeavor, I was technical lead on the viral genomics team, supporting collaborations with local and international global leaders. I continued to develop methods for NGS characterization, specifically for single-cell sequencing and analysis of antigen-specific T Cells at Repertoire Immune Medicines. At GreenLight Biosciences and Orbital Therapeutics, I led platform development teams in RNA genetic medicines, pushing the limit of mRNA modalities by making progress through innovation in RNA architecture, protein durability, and nonviral formulation designs. These genetic medicines required an understanding of disease biology for diverse indications such as Hemophilia, Sickle Cell Disease (SCD), and Systemic Lupus Erythematosus (SLE).

As a biotechnology consultant and advisor, I collaborate with organizations to support experimental and construct design, develop and optimize methods, streamline logistics and operations, prepare technical and competitive intelligence analyses, and provide project guidance.